Melanoma Global Clinical Trials Review, H2, 2017

Melanoma Global Clinical Trials Review, H2, 2017


  • Products Id :- GDHC4767CTIDB
  • |
  • Pages: 1302
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Melanoma Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, "Melanoma Global Clinical Trials Review, H2, 2017" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Melanoma to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Melanoma to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Melanoma Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Melanoma

Dec 13, 2017: Enrollment of First Patient in Investigator-Initiated Clinical Trial for Telomelysin (OBP-301)-pembrolizumab combination therapy

Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma

Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance

Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017

Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO

Nov 07, 2017: Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics

Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology 130

Secondary Research 130

About GlobalData 130

Contact Us 130

Disclaimer 130

Source

List of Figures

Melanoma Therapeutics, Global, Clinical Trials by Region (%), 2017*

Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*

Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*

Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*

Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*

Melanoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017*

Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*

Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*

Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017*

Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*

Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*

Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017*

Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*

Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*

Melanoma Therapeutics, Global, Clinical Trials by Phase (%), 2017*

Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*

Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*

Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*

Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016

Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*

Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*

Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*

Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

GlobalData Methodology 130

List of Tables

Melanoma Therapeutics, Global, Clinical Trials by Region, 2017*

Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*

Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*

Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*

Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*

Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2017*

Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*

Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*

Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017*

Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*

Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*

Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017*

Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*

Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*

Melanoma Therapeutics, Global, Clinical Trials by Phase, 2017*

Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017*

Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*

Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*

Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016

Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*

Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*

Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*

Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bristol-Myers Squibb Co

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Novartis AG

GlaxoSmithKline Plc

AstraZeneca Plc

Pfizer Inc

Sarah Cannon Research Institute LLC

Eisai Co Ltd

Amgen Inc

select a license
Single User License
USD 2500 INR 179475
Site License
USD 5000 INR 358950
Corporate User License
USD 7500 INR 538425

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com